Chemotherapy for older women with early breast cancer

Clinical Oncology

Volumn 17, Issue 4, 2005, Pages 244-248

  Leonard, R C F ^a   Mallinovszky, K M ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Breast cancer; Chemotherapy; Older

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CAPECITABINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; METHOTREXATE; PREDNISONE; TAMOXIFEN; TRASTUZUMAB; VINCRISTINE;

ADVANCED CANCER; AGE; AGED; ALOPECIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER INCIDENCE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMORBIDITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; ELDERLY CARE; FEBRILE NEUTROPENIA; FEMALE; FUNCTIONAL ASSESSMENT; HEART INJURY; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; LYMPH NODE METASTASIS; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SURGICAL TECHNIQUE; UNITED KINGDOM;

EID: 19344369788     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2005.02.002     Document Type: Article

References (42)

1. Cancer Research UK Breast cancer factsheet 2002 Cancer Research UK London
2. M. Vercelli A. Quaglia C. Casella et al. Relative survival in elderly cancer patients in Europe Eur J Cancer 34 1998 2264-2270
3. R. Yancik Cancer burden in the aged: An epidemiologic and demographic overview Cancer 80 1997 1273-1283
4. Government Actuary's Department. Interim life tables: Expectation of life based on data for the years 2000-2002. www.gad.gov.uk/Life_Tables/ Interim_life_tables.htm
5. R. Yancik L.G. Ries J.W. Yates Breast cancer in ageing women: A population based study in stage, surgery and survival Cancer 63 1989 976-981
6. L. Bergmann G. Dekker E.H.M. van Kerkhoff H.L. Peterse J.A. van Dongen F.E. van Leeuwen The influence of age and co-morbidity on treatment choice and its effect on survival in elderly patients with breast cancer Breast Cancer Res Treat 18 1991 189-198
7. L.M. Martin C. le Pechoux E. Calitchi et al. Management of breast cancer in the elderly Eur J Cancer 30A 1996 590-596
8. N.J. Turner R.A. Haward G.P. Mulley P.J. Selby Cancer in old age - is it inadequately investigated and treated? BMJ 319 1999 309-312
9. L. Hutchins J. Unger J. Crowley C.A. Coltman K.S. Albain Under representation of patients 65 years of age or older in cancer treatment trials N Engl J Med 341 1999 2061-2067
10. Early Breast Cancer Trialists' Collaborative Group Polychemotherapy for early breast cancer: An overview of the randomised trials Lancet 352 1998 930-942
11. A.B. Kornblith M. Kemeny B.L. Peterson et al. Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials Cancer 95 2002 989-996
12. R.P. A'Hern I.E. Smith S.R. Ebbs Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens Br J Cancer 67 1993 801-805
13. M.N. Levine V.H. Bramwell K.I. Pritchard et al. Randomised trial of intensive cyclophosphamide, epirubicin and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil CMF in premenopausal women with node-positive breast cancer J Clin Oncol 16 1998 2651-2658
14. A. Moliterni G. Bonadonna P. Valagussa L. Ferrari M. Zambetti Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes J Clin Oncol 9 1991 1124-1130
15. M. Piccart A. Di Leo M. Beauduin et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer J Clin Oncol 19 2001 3103-3110
16. C.J. Poole H.M. Earl L. Dunn et al. NEAT [National Epoirubicin Trial] and SCTBG BR9601 [Scottish Cancer Trials Breast Group] phase III adjuvant breast trials show a significant relapse-free and overall survival advantage for sequential ECMF [abstract 13] Proc Am Soc Clin Oncol 2003 22
17. D.R. Budman D.A. Berry C.T. Cirrincione et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B J Natl Cancer Inst 90 1998 1205-1211
18. F. Fata A. Mirza G. Craig et al. Efficacy of adjuvant chemotherapy in elderly patients with colon carcinoma: A 10-year experience of the Geisinger Medical Center Cancer 94 2002 1931-1938
19. P. Sonneveld M. de Ridder H. van der Lelie et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy J Clin Oncol 13 1995 2530-2539
20. G. Curigliano R. Gennari N. Rotmasz Breast cancer in elderly women: features of disease presentation and choice of adjuvant therapies compared with younger postmenopausal patients [abstract 3065] Proc Am Soc Clin Oncol 22 2003 762
21. H.B. Muss S.H. Woolf A. Berry et al. Older women with node positive [N+] breast cancer [BC] get similar benefits from adjuvant chemotherapy [Adj] as younger patients [pts]: The Cancer and Leukemia Group B [CALGB] experience [abstract 11] Proc Am Soc Clin Oncol 22 2003 4
22. International Breast Cancer Study Group Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph-node-negative breast cancer: A randomized trial J Natl Cancer Inst 94 2002 1054-1065
23. B. Fisher J. Dignam E.P. Mamounas et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: Eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil J Clin Oncol 14 1996 1982-1992
24. J.A. Wils J.M. Bliss M. Marty et al. Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group J Clin Oncol 17 1999 1988-1998
25. L. Balducci C.H. Hardy G.H. Lyman Hemopoietic factors in the older patient Curr Opin Hematol 8 2001 170-187
26. K. Christman H.B. Muss D. Case V. Stanley Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience JAMA 268 1992 57-62
27. N.K. Ibrahim D.K. Frye A.U. Buzdar R.S. Walters G.N. Hortobagyi Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome Arch Intern Med 156 1996 882-888
28. N.K. Ibrahim A.V. Buzdar L. Asmar et al. Doxorubicin based adjuvant chemotherapy in elderly breast cancer patients. The M.D. Anderson experience with long term follow up Ann Oncol 11 2000 1-5
29. D. Crivellari M. Bonetti M. Castiglione-Gertsch et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII J Clin Oncol 18 2000 1412-1422
30. E.C. Dees S. O'Reilly S.N. Goodman et al. A prospective pharmacological evaluation of age-related chemotherapy toxicity in older women Cancer Invest 18 2000 521-529
31. H. Ozer J.O. Armitage C.L. Bennett et al. Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines J Clin Oncol 8 2000 3558-3585
32. L. Balducci G.H. Lyman Patients aged >70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy [comment] J Clin Oncol 19 2001 1583-1585
33. L. Balducci J. Yates General guidelines for the management of older patients with cancer Oncology [Huntingt] 14 2000 221-227
34. A. Allen The cardiotoxicity of chemotherapeutic drugs Semin Oncol 19 1992 529-542
35. L. Balducci M. Extermann Management of cancer in the older person: A practical approach Oncologist 5 2000 224-237
36. B.N. Stein N.J. Petrelli H.O. Douglas et al. Age and sex are independent predictors of 5-fluorouracil toxicity Cancer 75 1995 11-17
37. L. Balducci M.B. Corcoran Antineoplastic chemotherapy of the older cancer patient Hematol Oncol Clin North Am 14 2000 193-212
38. D. Cova G. Beretta L. Balducci Cancer chemotherapy in the older patient In: L. Balducci G.H. Lyman W.B. Ershler editors Comprehensive geriatric oncology 1998 Harwood Academic Publishers Amsterdam 429-442
39. R.S. Gelman S.G. Taylor Cyclophosphamide, methotrexate and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer. The elimination of age trends in toxicity by using doses based on creatinine clearance J Clin Oncol 2 1984 1406-1414
40. D.B. Reuben L.V. Rubenstein S.H. Hirsch et al. Value of functional status as a predictor of mortality: Results of a prospective study Am J Med 93 1992 663-669
41. W.A. Santariano D.R. Ragland The effect of co-morbidity on 3-year survival of women with primary breast cancer Ann Intern Med 120 1994 104-110
42. M. Extermann Assessment of the older cancer patient Hematol Oncol Clin North Am 14 2000 63-77